US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Boundless Bio, Inc.

1.11

0.0000

Post-market: 1.110.00000.00%16:00 EDT

Volume:156.70K

Turnover:174.18K

Market Cap:24.85M

PE:-0.43

High:1.14

Open:1.11

Low:1.10

Close:1.11

52wk High:1.78

52wk Low:0.9612

Shares:22.39M

Float Shares:16.46M

Volume Ratio:2.31

T/O Rate:0.95%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.6027

EPS(LYR):-2.6027

ROE:-46.69%

ROA:-21.86%

PB:0.25

PE(LYR):-0.43

Loading ...

Overview Company News Filings

Boundless Bio to present oral kinesin degrader program at AACR Annual Meeting 2026

Boundless Bio Inc. publishes corporate presentation on ecDNA-directed cancer therapies and BBI-940 Phase 1 trial

Boundless Bio Q4 EPS $(0.58) Misses $(0.52) Estimate

Boundless Bio Q4 net loss narrows 22% to USD 12.89 million as R&D spending falls 26% to USD 9.82 million

Boundless Bio Inc - Expects Cash to Fund Operations Into the Second Half of 2028

THOMSON REUTERS

Boundless Bio Inc - Q4 EPS $-0.58

THOMSON REUTERS

Press Release: Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Boundless Bio CEO Zachary Hornby to Join Fireside Chat at Leerink Global Healthcare Conference

Boundless Bio Advances New Breast Cancer Drug BBI-940 Into First-in-Human Trial

Press Release: Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance

Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Boundless ceases enrollment of Phase 1/2 Potentiate trial of BBI-355, BBI-825

Boundless Bio Unveils ecDNA-Directed Cancer Therapy Strategy in New Presentation

Boundless Bio Inc: Bbi-940 Ind Accepted; Initiation of First-in-Human Clinical Trial on Track for First Half of 2026

THOMSON REUTERS

Boundless Bio Inc: Portfolio Prioritization, Including Discontinuation of Potentiate Trial, Extends Operating Runway Into H2 2028

THOMSON REUTERS

FDA Accepts IND Application for Boundless Bio's BBI-940

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM

Boundless Bio Terminates Early-Stage BBI-825 Cancer Trial: What Investors Should Know

21shares launches BOLD ETP combining bitcoin and gold in a single regulated product

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BOLD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BOLD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BOLD\",,,,,undefined,":{"symbol":"BOLD","market":"US","secType":"STK","nameCN":"Boundless Bio, Inc.","latestPrice":1.11,"timestamp":1774641600000,"preClose":1.11,"halted":0,"volume":156696,"hourTrading":{"tag":"盘后","latestPrice":1.11,"preClose":1.11,"latestTime":"16:00 EDT","volume":16,"amount":17.76,"timestamp":1774641607951,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0,"floatShares":16462050,"shares":22385611,"eps":-2.602728,"marketStatus":"Market Closed","change":0,"latestTime":"03-27 16:00:00 EDT","open":1.108,"high":1.14,"low":1.1,"amount":174182.0107,"amplitude":0.036036,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.602728,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1711598400000,"exchange":"NASDAQ","adjPreClose":1.11,"postHourTrading":{"tag":"盘后","latestPrice":1.11,"preClose":1.11,"latestTime":"16:00 EDT","volume":16,"amount":17.76,"timestamp":1774641607951,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.306911},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BOLD\",,,,,undefined,":{"symbol":"BOLD","floatShares":16462050,"roa":"-21.86%","roe":"-46.69%","lyrEps":-2.602728,"volumeRatio":2.306911,"shares":22385611,"dividePrice":0,"high":1.14,"amplitude":0.036036,"preClose":1.11,"low":1.1,"week52Low":0.9612,"pbRate":"0.25","week52High":1.78,"institutionHeld":0,"latestPrice":1.11,"eps":-2.602728,"divideRate":0,"volume":156696,"delay":0,"ttmEps":-2.602728,"open":1.108,"prevYearClose":1.2,"prevWeekClose":1.19,"prevMonthClose":1.16,"prevQuarterClose":1.2,"fiveDayClose":1.19,"twentyDayClose":1.16,"sixtyDayClose":1.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BOLD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-09","symbol":"BOLD","fiscalQuarterEnding":"2025/12","expectedEps":-0.44,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1773028800000,"reportTimeType":"pre","actualEps":-0.58},{"market":"US","date":"2025-11-05","symbol":"BOLD","fiscalQuarterEnding":"2025/09","expectedEps":-0.53,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.62},{"market":"US","date":"2025-08-05","symbol":"BOLD","fiscalQuarterEnding":"2025/06","expectedEps":-0.75,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"pre","actualEps":-0.7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BOLD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BOLD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":2,"updateTime":1748923200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BOLD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BOLD","date":"2026-03-27","current":-0.426476,"percent":0.73,"low":-7.197589,"twenty":-1.372432,"median":-0.573359,"eighty":-0.410208,"high":-0.344156,"avg":-1.177424,"sd":1.318297,"marketCap":24872048},"quantilePoints":[{"date":"2024-03-28","current":-7.197589,"twenty":-7.197589,"median":-7.197589,"eighty":-7.197589,"marketCap":355805632},{"date":"2024-04-05","current":-5.848041,"twenty":-6.410353,"median":-6.108954,"eighty":-6.050474,"marketCap":289092076},{"date":"2024-04-12","current":-5.231748,"twenty":-6.126948,"median":-5.947008,"eighty":-5.398192,"marketCap":258626218},{"date":"2024-04-19","current":-5.083297,"twenty":-6.09096,"median":-5.501658,"eighty":-5.078799,"marketCap":251287727},{"date":"2024-04-26","current":-5.429681,"twenty":-6.050474,"median":-5.339712,"eighty":-4.853874,"marketCap":268410873},{"date":"2024-05-03","current":-4.071136,"twenty":-5.947008,"median":-5.193511,"eighty":-4.750409,"marketCap":201252560},{"date":"2024-05-10","current":-4.093629,"twenty":-5.848041,"median":-5.078799,"eighty":-4.498493,"marketCap":202364453},{"date":"2024-05-17","current":-4.480499,"twenty":-5.605123,"median":-4.907856,"eighty":-4.413022,"marketCap":221489005},{"date":"2024-05-24","current":-4.735651,"twenty":-5.429681,"median":-4.853874,"eighty":-4.413022,"marketCap":234102149},{"date":"2024-05-31","current":-3.818758,"twenty":-5.40449,"median":-4.780666,"eighty":-4.267271,"marketCap":202947870},{"date":"2024-06-07","current":-4.028119,"twenty":-5.351408,"median":-4.637315,"eighty":-4.062533,"marketCap":214074398},{"date":"2024-06-14","current":-2.746826,"twenty":-5.256939,"median":-4.498493,"eighty":-3.894843,"marketCap":145980047},{"date":"2024-06-21","current":-1.997311,"twenty":-5.233547,"median":-4.480499,"eighty":-3.836344,"marketCap":106147077},{"date":"2024-06-28","current":-1.62046,"twenty":-5.185863,"median":-4.433265,"eighty":-3.622795,"marketCap":86119326},{"date":"2024-07-05","current":-1.737702,"twenty":-5.126483,"median":-4.318554,"eighty":-2.862394,"marketCap":92350182},{"date":"2024-07-12","current":-1.708392,"twenty":-5.081498,"median":-4.206091,"eighty":-2.280368,"marketCap":90792468},{"date":"2024-07-19","current":-1.490655,"twenty":-5.078799,"median":-4.082382,"eighty":-1.861645,"marketCap":79220879},{"date":"2024-07-26","current":-1.553464,"twenty":-5.032015,"median":-4.019745,"eighty":-1.783761,"marketCap":82558837},{"date":"2024-08-02","current":-1.33154,"twenty":-4.961394,"median":-3.883354,"eighty":-1.756126,"marketCap":70764718},{"date":"2024-08-09","current":-1.285481,"twenty":-4.955327,"median":-3.848068,"eighty":-1.688293,"marketCap":68316881},{"date":"2024-08-16","current":-1.276053,"twenty":-4.909884,"median":-3.776885,"eighty":-1.61376,"marketCap":73657615},{"date":"2024-08-23","current":-1.441824,"twenty":-4.830482,"median":-3.580085,"eighty":-1.533365,"marketCap":83226429},{"date":"2024-08-30","current":-1.395563,"twenty":-4.789503,"median":-2.891285,"eighty":-1.49233,"marketCap":80556062},{"date":"2024-09-06","current":-1.206661,"twenty":-4.774615,"median":-2.543744,"eighty":-1.430642,"marketCap":69652065},{"date":"2024-09-13","current":-1.383997,"twenty":-4.747457,"median":-2.265294,"eighty":-1.38631,"marketCap":79888471},{"date":"2024-09-20","current":-1.696264,"twenty":-4.696317,"median":-1.886349,"eighty":-1.383997,"marketCap":97913446},{"date":"2024-09-27","current":-1.306894,"twenty":-4.531782,"median":-1.821447,"eighty":-1.360095,"marketCap":75437859},{"date":"2024-10-04","current":-1.225936,"twenty":-4.502092,"median":-1.785855,"eighty":-1.334651,"marketCap":70764718},{"date":"2024-10-11","current":-1.164254,"twenty":-4.498493,"median":-1.762826,"eighty":-1.315376,"marketCap":67204229},{"date":"2024-10-18","current":-1.175819,"twenty":-4.494894,"median":-1.752358,"eighty":-1.306512,"marketCap":67871820},{"date":"2024-10-25","current":-1.125702,"twenty":-4.475101,"median":-1.708392,"eighty":-1.277939,"marketCap":64978923},{"date":"2024-11-01","current":-1.148833,"twenty":-4.453508,"median":-1.660521,"eighty":-1.239044,"marketCap":66314106},{"date":"2024-11-08","current":-1.278189,"twenty":-4.445411,"median":-1.62046,"eighty":-1.227478,"marketCap":78044967},{"date":"2024-11-15","current":-1.099243,"twenty":-4.400426,"median":-1.603711,"eighty":-1.225936,"marketCap":67118671},{"date":"2024-11-22","current":-0.858213,"twenty":-4.337447,"median":-1.553464,"eighty":-1.206661,"marketCap":52401620},{"date":"2024-11-29","current":-0.996988,"twenty":-4.287064,"median":-1.515072,"eighty":-1.18353,"marketCap":60875074},{"date":"2024-12-06","current":-1.033507,"twenty":-4.282566,"median":-1.492749,"eighty":-1.171964,"marketCap":63104930},{"date":"2024-12-13","current":-0.898385,"twenty":-4.206091,"median":-1.45339,"eighty":-1.168109,"marketCap":54854462},{"date":"2024-12-20","current":-0.94586,"twenty":-4.174602,"median":-1.427126,"eighty":-1.164254,"marketCap":57753275},{"date":"2024-12-27","current":-0.931252,"twenty":-4.109824,"median":-1.4052,"eighty":-1.151917,"marketCap":56861333},{"date":"2025-01-03","current":-0.978728,"twenty":-4.080133,"median":-1.38978,"eighty":-1.137518,"marketCap":59760146},{"date":"2025-01-10","current":-0.883777,"twenty":-4.053929,"median":-1.382892,"eighty":-1.125702,"marketCap":53962520},{"date":"2025-01-17","current":-0.923948,"twenty":-4.024769,"median":-1.357011,"eighty":-1.113366,"marketCap":56415361},{"date":"2025-01-24","current":-0.880125,"twenty":-4.002159,"median":-1.351229,"eighty":-1.080253,"marketCap":53739534},{"date":"2025-01-31","current":-0.836301,"twenty":-3.925951,"median":-1.335808,"eighty":-1.010135,"marketCap":51063706},{"date":"2025-02-07","current":-0.810737,"twenty":-3.894843,"median":-1.330025,"eighty":-0.986762,"marketCap":49502807},{"date":"2025-02-14","current":-0.818041,"twenty":-3.863491,"median":-1.312677,"eighty":-0.98238,"marketCap":49948778},{"date":"2025-02-21","current":-0.715786,"twenty":-3.86063,"median":-1.307149,"eighty":-0.967772,"marketCap":43705181},{"date":"2025-02-28","current":-0.70483,"twenty":-3.848068,"median":-1.306417,"eighty":-0.938556,"marketCap":43036224},{"date":"2025-03-07","current":-0.617183,"twenty":-3.818758,"median":-1.293401,"eighty":-0.934904,"marketCap":37684569},{"date":"2025-03-14","current":-0.613531,"twenty":-3.802009,"median":-1.278189,"eighty":-0.9276,"marketCap":37461584},{"date":"2025-03-21","current":-0.642747,"twenty":-3.751762,"median":-1.256474,"eighty":-0.920296,"marketCap":39245469},{"date":"2025-03-28","current":-0.511724,"twenty":-3.651268,"median":-1.237502,"eighty":-0.912992,"marketCap":33447843},{"date":"2025-04-04","current":-0.443494,"twenty":-3.580085,"median":-1.233647,"eighty":-0.891081,"marketCap":28988130},{"date":"2025-04-11","current":-0.416203,"twenty":-3.232545,"median":-1.225936,"eighty":-0.861865,"marketCap":27204245},{"date":"2025-04-17","current":-0.484432,"twenty":-3.075105,"median":-1.212454,"eighty":-0.839223,"marketCap":31663958},{"date":"2025-04-25","current":-0.50149,"twenty":-2.80461,"median":-1.206661,"eighty":-0.818041,"marketCap":32778886},{"date":"2025-05-02","current":-0.547545,"twenty":-2.616184,"median":-1.18353,"eighty":-0.802703,"marketCap":35789192},{"date":"2025-05-09","current":-0.490678,"twenty":-2.519877,"median":-1.175819,"eighty":-0.736237,"marketCap":32233147},{"date":"2025-05-16","current":-0.562236,"twenty":-2.343176,"median":-1.171964,"eighty":-0.7041,"marketCap":36933814},{"date":"2025-05-23","current":-0.531568,"twenty":-2.272831,"median":-1.168109,"eighty":-0.640556,"marketCap":34919242},{"date":"2025-05-30","current":-0.398676,"twenty":-2.104504,"median":-1.164254,"eighty":-0.625217,"marketCap":26189432},{"date":"2025-06-06","current":-0.398676,"twenty":-1.939527,"median":-1.156544,"eighty":-0.615722,"marketCap":26189432},{"date":"2025-06-13","current":-0.371416,"twenty":-1.883418,"median":-1.150761,"eighty":-0.59381,"marketCap":24398701},{"date":"2025-06-20","current":-0.354379,"twenty":-1.864994,"median":-1.144978,"eighty":-0.584315,"marketCap":23279495},{"date":"2025-06-27","current":-0.364601,"twenty":-1.841546,"median":-1.129558,"eighty":-0.573359,"marketCap":23951019},{"date":"2025-07-03","current":-0.364601,"twenty":-1.81726,"median":-1.125702,"eighty":-0.562917,"marketCap":23951019},{"date":"2025-07-11","current":-0.402084,"twenty":-1.799673,"median":-1.119919,"eighty":-0.547886,"marketCap":26413273},{"date":"2025-07-18","current":-0.402084,"twenty":-1.792136,"median":-1.099243,"eighty":-0.532375,"marketCap":26413273},{"date":"2025-07-25","current":-0.425936,"twenty":-1.772875,"median":-1.068201,"eighty":-0.524876,"marketCap":27980162},{"date":"2025-08-01","current":-0.403787,"twenty":-1.762826,"median":-1.033507,"eighty":-0.512406,"marketCap":26525194},{"date":"2025-08-08","current":-0.396302,"twenty":-1.761988,"median":-0.996988,"eighty":-0.507716,"marketCap":25517908},{"date":"2025-08-15","current":-0.406731,"twenty":-1.757801,"median":-0.986032,"eighty":-0.494667,"marketCap":26189432},{"date":"2025-08-22","current":-0.396302,"twenty":-1.753614,"median":-0.98238,"eighty":-0.472151,"marketCap":25517908},{"date":"2025-08-29","current":-0.396302,"twenty":-1.747752,"median":-0.978728,"eighty":-0.443077,"marketCap":25517908},{"date":"2025-09-05","current":-0.392826,"twenty":-1.737702,"median":-0.967772,"eighty":-0.423026,"marketCap":25294066},{"date":"2025-09-12","current":-0.403255,"twenty":-1.708392,"median":-0.944034,"eighty":-0.416203,"marketCap":25965590},{"date":"2025-09-19","current":-0.396302,"twenty":-1.696264,"median":-0.938556,"eighty":-0.40938,"marketCap":25517908},{"date":"2025-09-26","current":-0.392826,"twenty":-1.674894,"median":-0.934904,"eighty":-0.406731,"marketCap":25294066},{"date":"2025-10-03","current":-0.420637,"twenty":-1.646147,"median":-0.9276,"eighty":-0.406731,"marketCap":27084797},{"date":"2025-10-10","current":-0.444971,"twenty":-1.624647,"median":-0.925774,"eighty":-0.406731,"marketCap":28651686},{"date":"2025-10-17","current":-0.490163,"twenty":-1.62046,"median":-0.920296,"eighty":-0.408899,"marketCap":31561623},{"date":"2025-10-24","current":-0.490163,"twenty":-1.616272,"median":-0.914818,"eighty":-0.40938,"marketCap":31561623},{"date":"2025-10-31","current":-0.479734,"twenty":-1.612085,"median":-0.912992,"eighty":-0.40938,"marketCap":30890099},{"date":"2025-11-07","current":-0.456671,"twenty":-1.595336,"median":-0.898385,"eighty":-0.410208,"marketCap":28204003},{"date":"2025-11-14","current":-0.434925,"twenty":-1.566026,"median":-0.891081,"eighty":-0.410208,"marketCap":26860956},{"date":"2025-11-21","current":-0.402305,"twenty":-1.553464,"median":-0.870995,"eighty":-0.410208,"marketCap":24846384},{"date":"2025-11-28","current":-0.424052,"twenty":-1.526666,"median":-0.858213,"eighty":-0.409519,"marketCap":26189432},{"date":"2025-12-05","current":-0.398681,"twenty":-1.516051,"median":-0.836301,"eighty":-0.408465,"marketCap":24622543},{"date":"2025-12-12","current":-0.416803,"twenty":-1.508938,"median":-0.819867,"eighty":-0.409284,"marketCap":25741749},{"date":"2025-12-19","current":-0.460295,"twenty":-1.497355,"median":-0.814389,"eighty":-0.40938,"marketCap":28427845},{"date":"2025-12-26","current":-0.438549,"twenty":-1.49233,"median":-0.803433,"eighty":-0.409484,"marketCap":27084797},{"date":"2026-01-02","current":-0.434925,"twenty":-1.481917,"median":-0.796129,"eighty":-0.409816,"marketCap":26860956},{"date":"2026-01-09","current":-0.474793,"twenty":-1.462642,"median":-0.734046,"eighty":-0.410208,"marketCap":29323210},{"date":"2026-01-16","current":-0.453047,"twenty":-1.448764,"median":-0.70483,"eighty":-0.411047,"marketCap":27980162},{"date":"2026-01-23","current":-0.460295,"twenty":-1.439029,"median":-0.701178,"eighty":-0.412481,"marketCap":28427845},{"date":"2026-01-30","current":-0.427676,"twenty":-1.427558,"median":-0.657354,"eighty":-0.413179,"marketCap":26413273},{"date":"2026-02-06","current":-0.395057,"twenty":-1.422549,"median":-0.629965,"eighty":-0.410208,"marketCap":24398701},{"date":"2026-02-13","current":-0.409554,"twenty":-1.406357,"median":-0.620835,"eighty":-0.409554,"marketCap":25294066},{"date":"2026-02-20","current":-0.427676,"twenty":-1.403273,"median":-0.619009,"eighty":-0.409554,"marketCap":26413273},{"date":"2026-02-27","current":-0.420427,"twenty":-1.395563,"median":-0.613531,"eighty":-0.409554,"marketCap":25965590},{"date":"2026-03-06","current":-0.40593,"twenty":-1.383997,"median":-0.593445,"eighty":-0.409554,"marketCap":25070225},{"date":"2026-03-13","current":-0.431227,"twenty":-1.383997,"median":-0.584315,"eighty":-0.409554,"marketCap":25096121},{"date":"2026-03-20","current":-0.442778,"twenty":-1.381787,"median":-0.575865,"eighty":-0.409554,"marketCap":25768338},{"date":"2026-03-27","current":-0.427377,"twenty":-1.372432,"median":-0.573359,"eighty":-0.410208,"marketCap":24872048}],"updateTime":1774698355680},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BOLD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620403203","title":"Boundless Bio to present oral kinesin degrader program at AACR Annual Meeting 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620403203","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620403203?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:52","pubTimestamp":1773780757,"startTime":"0","endTime":"0","summary":"Boundless Bio will present a poster at the American Association for Cancer Research  Annual Meeting 2026, held April 17-22, 2026 in San Diego, California. The poster session is scheduled for April 21, 2026, 2:00 PM-5:00 PM PT . The presentation will cover preclinical work on BBI-940, an oral kinesin degrader program, under abstract LB361.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL2rWVQc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOLD","LU2095319765.USD","BK4139","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BK4585","IE00BN0W2T93.GBP","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","NDAQ","LU0314104364.USD","BK4588","LU2210150020.SGD","LU2210149790.SGD","SG9999014013.SGD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4112"],"gpt_icon":0},{"id":"2618258656","title":"Boundless Bio Inc. publishes corporate presentation on ecDNA-directed cancer therapies and BBI-940 Phase 1 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2618258656","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618258656?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:59","pubTimestamp":1773057566,"startTime":"0","endTime":"0","summary":"Boundless Bio outlined its strategy to develop extrachromosomal DNA -directed therapies for oncogene-amplified cancers, describing ecDNA as a driver of amplification and treatment resistance. The company said about 25% of cancer patients have amplified oncogenes, and about 54% of high-copy number oncogene amplifications are detected on ecDNA. Boundless Bio highlighted BBI-940, an oral kinesin degrader, with the KOMODO-1 Phase 1 first-in-human trial underway in patients with ER+/HER2- breast cancer and TNBC-LAR. It also described its Spyglass discovery platform, which it said uses ecDNA biology to identify synthetic lethal targets, and referenced additional programs including BBI-355  and BBI-825 .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL9snmqg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOLD","BK4139"],"gpt_icon":0},{"id":"2618288906","title":"Boundless Bio Q4 EPS $(0.58) Misses $(0.52) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2618288906","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618288906?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:13","pubTimestamp":1773054787,"startTime":"0","endTime":"0","summary":"Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.52) by 11.54 percent. This is a 21.62 percent increase over losses of $(0.74) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51122807/boundless-bio-q4-eps-0-58-misses-0-52-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOLD"],"gpt_icon":0},{"id":"2618640400","title":"Boundless Bio Q4 net loss narrows 22% to USD 12.89 million as R&D spending falls 26% to USD 9.82 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640400","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640400?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:03","pubTimestamp":1773054189,"startTime":"0","endTime":"0","summary":"Boundless Bio reported a Q4 net loss of USD 12.89 million, narrowing 22% from the prior-year quarter. R&D expenses fell 26% to USD 9.82 million in Q4, while G&A expenses declined 16% to USD 4.19 million. For FY 2025, net loss was USD 58.2 million, narrowing 11%, as R&D expenses decreased 19% to USD 44.85 million. Cash, cash equivalents and short-term investments totaled USD 107.58 million at year-end, and the company said this is expected to fund operations into the second half of 2028 through an anticipated initial clinical proof-of-concept readout from the KOMODO-1 trial of BBI-940.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDLb8BKSt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210149790.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","SG9999014013.SGD","BK4588","BOLD","LU0314104364.USD","LU2095319765.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","BK4585","IE00B64PRP62.GBP","NDAQ","IE00BGHQF748.EUR","BK4139","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2618407196","title":"Boundless Bio Inc - Expects Cash to Fund Operations Into the Second Half of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2618407196","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618407196?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA7K1ZC6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BOLD"],"gpt_icon":0},{"id":"2618026640","title":"Boundless Bio Inc - Q4 EPS $-0.58","url":"https://stock-news.laohu8.com/highlight/detail?id=2618026640","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618026640?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA7K1ZC6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BOLD"],"gpt_icon":0},{"id":"2618640473","title":"Press Release: Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640473","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640473?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054000,"startTime":"0","endTime":"0","summary":"KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment. $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1. SAN DIEGO, March 09, 2026  -- Boundless Bio , a clinical-stage oncology company interrogating extrachromosomal DNA  biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter and full year ended December 31, 2025.\"With the KOMODO-1 trial of BBI-940 actively enrolling, we are excited to evaluate this potentially first-in-class oral Kinesin degrader in patients with breast cancer who are seeking new treatment options. BBI-940 is designed to disrupt ecDNA segregation and inheritance, a differentiated mechanism for targeting chromosomally unstable cancers. The Boundless team is focused on clinical execution and reaching an initial proof-of-concept readout wit","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BOLD"],"gpt_icon":0},{"id":"2616532755","title":"Boundless Bio CEO Zachary Hornby to Join Fireside Chat at Leerink Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2616532755","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616532755?lang=en_us&edition=fundamental","pubTime":"2026-03-04 20:02","pubTimestamp":1772625779,"startTime":"0","endTime":"0","summary":"Boundless Bio CEO Zachary Hornby to Join Fireside Chat at Leerink Global Healthcare Conference               Boundless Bio (Nasdaq: BOLD) said its President and CEO Zachary Hornby will participate in ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL2Vd4vc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4585","LU2210149790.SGD","BK4112","LU2210150020.SGD","LU2095319765.USD","SG9999014005.SGD","LU0314104364.USD","BK4588","SG9999014013.SGD","BOLD","IE00B3QW5Z07.USD","NDAQ","SG9999014021.USD","SG9999014039.USD","BK4139","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2611975346","title":"Boundless Bio Advances New Breast Cancer Drug BBI-940 Into First-in-Human Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2611975346","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611975346?lang=en_us&edition=fundamental","pubTime":"2026-02-13 00:31","pubTimestamp":1770913912,"startTime":"0","endTime":"0","summary":"Boundless Bio Inc. ($BOLD) announced an update on their ongoing clinical study. Boundless Bio Inc. (BOLD) has launched a first-in-human Phase 1 tri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/boundless-bio-advances-new-breast-cancer-drug-bbi-940-into-first-in-human-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/boundless-bio-advances-new-breast-cancer-drug-bbi-940-into-first-in-human-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BOLD"],"gpt_icon":0},{"id":"2610137659","title":"Press Release: Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2610137659","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610137659?lang=en_us&edition=fundamental","pubTime":"2026-02-12 14:00","pubTimestamp":1770876000,"startTime":"0","endTime":"0","summary":"-- FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by. growth of the three therapeutic areas of Oncology , Rare Disease.  and Neuroscience ; Somatuline sales growth of 4.3%1,with all other products, excluding Somatuline, achieving double-digit. -- FY 2025 core operating income of EUR1,294m, growing by 16.7% as reported,with a core operating margin of 35.2% of total sales, increasing by. -- 2025 continued pipeline expansion, driven by significant regulatory and. clinical milestones, integration of multiple preclinical assets with. global rights and innovative approaches, and a mid-stage candidate from. addition to the full data readout for IPN10200 in an aesthetics. PARIS, FRANCE, 12 February 2026 - Ipsen , a global specialty-care biopharmaceutical company, today presents its financial results for the full year  2025 and for the fourth quarter of 2025.\"In 2025, Ipsen delivered strong sales and profit growth,\" said David Loew, Chief Executive Officer, Ipsen. \"We contin","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOLD","R","EMA","BK4080","BK4022","BK4232","BK4081","BK4231","ADC","BK4139"],"gpt_icon":0},{"id":"2609372831","title":"Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2609372831","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609372831?lang=en_us&edition=fundamental","pubTime":"2026-02-05 20:00","pubTimestamp":1770292800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  05, 2026  (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/05/3232819/0/en/Boundless-Bio-to-Participate-in-the-Guggenheim-Emerging-Outlook-Biotech-Summit-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BOLD","BK4139","SMMF","LABU","BK4588","BK4585"],"gpt_icon":0},{"id":"2604718190","title":"Boundless ceases enrollment of Phase 1/2 Potentiate trial of BBI-355, BBI-825","url":"https://stock-news.laohu8.com/highlight/detail?id=2604718190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604718190?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:15","pubTimestamp":1768911345,"startTime":"0","endTime":"0","summary":"Following a strategic portfolio review, Boundless Bio (BOLD) has elected to cease enrollment of the Phase 1/2 Potentiate trial evaluating the combi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/boundless-ceases-enrollment-of-phase-1-2-potentiate-trial-of-bbi-355-bbi-825-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/boundless-ceases-enrollment-of-phase-1-2-potentiate-trial-of-bbi-355-bbi-825-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BOLD","BK4139"],"gpt_icon":0},{"id":"2604190194","title":"Boundless Bio Unveils ecDNA-Directed Cancer Therapy Strategy in New Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2604190194","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604190194?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:09","pubTimestamp":1768910989,"startTime":"0","endTime":"0","summary":"Boundless Bio Inc. has released a corporate presentation detailing its latest developments in cancer treatment targeting oncogene amplified cancers, which represent a significant unmet medical need with approximately 1.3 million new patients annually in major markets. The company highlights its focus on therapies directed at extrachromosomal DNA , a cancer-specific circular DNA implicated in oncogene amplification. Boundless Bio's drug discovery platform, Spyglass, is used to identify synthetic lethal targets in these cancers. The company’s pipeline includes BBI-940, an oral Kinesin degrader with an accepted IND and a clinical trial set to begin in the first half of 2026. In addition, four other ecDNA-selective targets are under development, with one at the hit-to-lead stage. Boundless Bio reports a cash runway expected to last into the second half of 2028, supporting continued research and development activities. You can access the full presentation through the link below.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL38nKtC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOLD","BK4139"],"gpt_icon":0},{"id":"2604190609","title":"Boundless Bio Inc: Bbi-940 Ind Accepted; Initiation of First-in-Human Clinical Trial on Track for First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2604190609","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604190609?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:05","pubTimestamp":1768910704,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YL0FC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BOLD","BK4139"],"gpt_icon":0},{"id":"2604190606","title":"Boundless Bio Inc: Portfolio Prioritization, Including Discontinuation of Potentiate Trial, Extends Operating Runway Into H2 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2604190606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604190606?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:05","pubTimestamp":1768910704,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YL0FC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BOLD","BK4139"],"gpt_icon":0},{"id":"2604919707","title":"FDA Accepts IND Application for Boundless Bio's BBI-940","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919707","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604919707?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:00","pubTimestamp":1768910424,"startTime":"0","endTime":"0","summary":"Boundless Bio Inc. announced that the U.S. Food and Drug Administration  has accepted its Investigational New Drug  application for its novel Kinesin oral degrader program, BBI-940. This regulatory acceptance enables Boundless Bio to proceed with the initiation of a first-in-human clinical trial, which is on track to begin in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boundless Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on January 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL3fH6SH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014021.USD","BK4112","BOLD","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014013.SGD","LU2210150020.SGD","BK4139","BK4588","NDAQ","SG9999014005.SGD","LU0314104364.USD","SG9999014039.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2604619056","title":"Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2604619056","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604619056?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:00","pubTimestamp":1768910400,"startTime":"0","endTime":"0","summary":"BBI-940 IND accepted; initiation of first-in-human clinical trial on trackfor the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/20/3221540/0/en/Boundless-Bio-Advances-Novel-Kinesin-Degrader-Program-BBI-940-and-Extends-Cash-Runway.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IND","BOLD"],"gpt_icon":0},{"id":"2604974881","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 06:55 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2604974881","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604974881?lang=en_us&edition=fundamental","pubTime":"2026-01-20 19:55","pubTimestamp":1768910100,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 06:55 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nAQN2LIB60:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BOLD"],"gpt_icon":0},{"id":"2604478990","title":"Boundless Bio Terminates Early-Stage BBI-825 Cancer Trial: What Investors Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2604478990","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604478990?lang=en_us&edition=fundamental","pubTime":"2026-01-17 00:31","pubTimestamp":1768581094,"startTime":"0","endTime":"0","summary":"Boundless Bio Inc. ($BOLD) announced an update on their ongoing clinical study. Study Overview The study, formally titled “An Open-Label, Multicent...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/boundless-bio-terminates-early-stage-bbi-825-cancer-trial-what-investors-should-know?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/boundless-bio-terminates-early-stage-bbi-825-cancer-trial-what-investors-should-know?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SSI","ISBC","BOLD","BK4211"],"gpt_icon":0},{"id":"2603504366","title":"21shares launches BOLD ETP combining bitcoin and gold in a single regulated product","url":"https://stock-news.laohu8.com/highlight/detail?id=2603504366","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603504366?lang=en_us&edition=fundamental","pubTime":"2026-01-13 17:00","pubTimestamp":1768294800,"startTime":"0","endTime":"0","summary":"Approved by Archax 12/01/2026 Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Ta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/13/3217495/0/en/21shares-launches-BOLD-ETP-combining-bitcoin-and-gold-in-a-single-regulated-product.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","03042","BK4139","BK4588","FCA","LSE","03008","BK1611","09439","BK4179","BK4594","FSCS","03439","09042","ETH","BK4601","BTC","83042","BOLD","IBIT","09008"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}]}}